Dynamic Technology Lab Private Ltd Makes New Investment in Charles River Laboratories International, Inc. (NYSE:CRL)

Dynamic Technology Lab Private Ltd purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 5,150 shares of the medical research company's stock, valued at approximately $951,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc boosted its holdings in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after acquiring an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. raised its position in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after purchasing an additional 65 shares during the last quarter. Pilgrim Partners Asia Pte Ltd acquired a new position in Charles River Laboratories International in the fourth quarter worth $48,000. Tortoise Investment Management LLC grew its holdings in shares of Charles River Laboratories International by 77.7% during the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after purchasing an additional 115 shares during the last quarter. Finally, Huntington National Bank grew its holdings in shares of Charles River Laboratories International by 120.6% during the fourth quarter. Huntington National Bank now owns 300 shares of the medical research company's stock worth $55,000 after purchasing an additional 164 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Activity at Charles River Laboratories International

In related news, CEO James C. Foster purchased 6,075 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was bought at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Birgit Girshick acquired 1,514 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The shares were bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the acquisition, the chief operating officer now owns 55,058 shares of the company's stock, valued at $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by insiders.

Analyst Ratings Changes

CRL has been the topic of several research reports. Morgan Stanley reduced their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. Citigroup upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and upped their target price for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. Barclays lowered their price target on shares of Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating for the company in a report on Thursday. Redburn Atlantic raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective on the stock in a report on Monday, March 3rd. Finally, Bank of America lowered their target price on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research note on Friday, December 13th. One equities research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $182.00.

Charles River Laboratories International Trading Down 6.3 %

Shares of NYSE:CRL traded down $6.26 during mid-day trading on Friday, reaching $93.69. The stock had a trading volume of 4,986,141 shares, compared to its average volume of 829,372. The firm has a 50 day simple moving average of $157.97 and a two-hundred day simple moving average of $177.65. Charles River Laboratories International, Inc. has a twelve month low of $92.05 and a twelve month high of $254.15. The firm has a market cap of $4.60 billion, a PE ratio of 624.65, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion for the quarter, compared to analysts' expectations of $983.63 million. During the same period last year, the firm posted $2.46 earnings per share. The business's quarterly revenue was down 1.1% compared to the same quarter last year. On average, research analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).